Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of
treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake
Time After Sleep Onset (PSG-WASO) and Polysomnography Number of Awakenings (PSG-NAW).
Secondary objectives:
- To evaluate the effects of eplivanserin 5mg/day as compared to placebo after 6 weeks of
treatment on other sleep parameters measured by PSG recordings (Total Sleep Time -
PSG-TST, Sleep Efficiency - PSG-SE, Latency to Persistent Sleep - PSG-LPS) and reported
by patients (Wake Time After Sleep Onset - pr-WASO, Number of Awakenings - pr-NAW, Total
Sleep Time - pr-TST, Quality of Sleep - QoS and Refreshing Quality of Sleep - RqoS).
- To evaluate the effects of eplivanserin 5mg/day on sleep architecture compared to
placebo.
- To evaluate the effect of eplivanserin 5mg/day on daytime functioning using the Sleep
Impact Scale (SIS), as compared with placebo after 6 weeks of treatment.
- To evaluate patient's impression of treatment effects using the Patient's Global
Impression questionnaire.
- To evaluate the potential for next-day residual effects (using patient's morning
questionnaire and psychometric tests) with eplivanserin 5mg/day as compared to placebo.
- To evaluate the potential for rebound insomnia following abrupt discontinuation of
eplivanserin 5mg/day in comparison with placebo.
- To evaluate the effect of eplivanserin, compared to placebo, on the quality of life of
patients with primary insomnia using the SF-36 Health Survey.
- To evaluate the clinical safety and tolerability of eplivanserin 5mg/day compared to
placebo.